Table 1.
Baseline characteristics of the CYP2C19 poor metabolisers
| Clopidogrel n = 32 |
Prasugrel n = 41 |
p-value | ||
|---|---|---|---|---|
| Age, mean (SD), years | 65.2 (10.2) | 64.2 (11.1) | 0.680 | |
| Sex, n (%) | Male | 22 (69) | 30 (73) | – |
| Female | 10 (31) | 11 (27) | 0.680 | |
| Race, n (%) | Caucasian | 32 (100) | 40 (98) | – |
| Asian | 0 (0) | 1 (2) | 0.370 | |
| Medical history, n (%) | Smoker | 8 (25) | 8 (20) | 0.600 |
| Diabetes mellitus | 7 (22) | 7 (17) | 0.630 | |
| Hypertension | 17 (53) | 14 (34) | 0.110 | |
| Hypercholesterolaemia | 9 (28) | 16 (39) | 0.340 | |
| Previous PCI | 14 (44) | 17 (41) | 0.750 | |
| Previous MI | 14 (44) | 22 (54) | 0.420 | |
| Previous CABG | 7 (22) | 13(32) | 0.350 | |
| Pharmacotherapy, n (%) | Beta-blocker | 23 (72) | 34 (83) | 0.260 |
| ACE inhibitor | 7 (22) | 13 (32) | 0.350 | |
CABG coronary artery bypass graft, MI myocardial infarction, PCI percutaneous intervention